key: cord-0936783-knha0153
authors: Mohamadian, Malihe; Chiti, Hossein; Shoghli, Alireza; Biglari, Sajjad; Parsamanesh, Negin; Esmaeilzadeh, Abdolreza
title: COVID‐19: Virology, biology and novel laboratory diagnosis
date: 2021-01-06
journal: J Gene Med
DOI: 10.1002/jgm.3303
sha: 5c82c0e073132879bf34867383113cdf7c680d93
doc_id: 936783
cord_uid: knha0153

BACKGROUND: At the end of December 2019, a novel coronavirus tentatively named SARS‐CoV‐2 in Wuhan, a central city in China, was announced by the World Health Organization. SARS‐CoV‐2 is an RNA virus that has become a major public health concern after the outbreak of the Middle East Respiratory Syndrome‐CoV (MERS‐CoV) and Severe Acute Respiratory Syndrome‐CoV (SARS‐CoV) in 2002 and 2012, respectively. As of 29 October 2020, the total number of COVID‐19 cases had reached over 44 million worldwide, with more than 1.17 million confirmed deaths. DISCUSSION: SARS‐CoV‐2 infected patients usually present with severe viral pneumonia. Similar to SARS‐CoV, the virus enters respiratory tract cells via the angiotensin‐converting enzyme receptor 2. The structural proteins play an essential role in budding the virus particles released from different host cells. To date, an approved vaccine or treatment option of a preventive character to avoid severe courses of COVID‐19 is still not available. CONCLUSIONS: In the present study, we provide a brief review of the general biological features of CoVs and explain the pathogenesis, clinical symptoms and diagnostic approaches regarding monitoring future infectivity and prevent emerging COVID‐19 infections.

In December 2019, a novel coronavirus (nCoV) termed "SARS-CoV- human and person to person. [3] [4] [5] In total, seven human coronaviruses (HCoVs) have now been discovered, including HCoV229E, HCoV-OC43, HCoV-NL63, HKU1, SARS-CoV, MERS-CoV and SARS-CoV-2. 6, 7 In the last two decades, SARS-CoV and MERS-CoV have caused epidemics with mortality rates of approximately 9.5% and 34.4%, respectively. 8 COVID-19 was the third highly epidemic disease to be detected, with a lower mortality rate than SARS and MERS, differing from country to country. According to WHO statistics, there are 45,678,440 (1 November 2020) confirmed cases in 219 countries caused by the high transmission capacity of SARS-CoV-2. 9 Hence, to characterize the acute infection in humans as a result of the SARS-CoV-2, scientists and governments have urgently taken decisive steps to monitor its outbreak and carry out etiological research. 10 In combination with advances in molecular Malihe Mohamadian and Hossein Chiti contributed equally to this work. technologies, the development of a viable vaccine appears to be imminent. 11, 12 The higher transmissibility, varied clinical manifestations and lower pathogenicity of COVID-19 could be a result of diversity in the biology and genome structure of the SARS-CoV-2 compared to SARS-CoV and MERS-CoV. 13, 14 This review focuses on the virus biology, clinical symptoms and potential diagnostic routes for achieve efficient prevention and reduction of COVID-19 mortality. teins. 16, 17 The first ORF contains approximately 65% of the viral genome and translates into either polyprotein pp1a (nsp1-11) or pp1ab (nsp1-16). Among them, six nsps (NSP3, NSP9, NSP10, NSP12, NSP15 and NSP16) play critical roles in viral replication. Other

ORFs encode structural and accessory proteins. 18, 19 The S protein is a transmembrane protein that facilitates the binding of viral envelop to angiotensin-converting enzyme 2 (ACE2) receptors expressed on host cell surfaces. Functionally, the spike protein is composed of receptor binding (S1) and cell membrane fusion (S2) subunits. 20 The N protein attaches to the viral genome and is involved in RNA replication, virion formation and immune evasion. The nucleocapsid protein also interacts with the nsp3 and M proteins. 21 The M protein is one of the most abundant and well-conserved proteins in the virion structure. This protein promotes the assembly and budding of viral particles through interaction with N and accessory proteins 3a and 7a. 22, 23 The E protein is the smallest component in the SARS-CoV-2 structure that facilitates the production, maturation and release of virions. 18 The most complex component of the coronaviruses genome is the receptor-binding domain (RBD) in the spike protein. 24, 25 Six RBD amino acids are necessary for attaching to the ACE2 receptor and hosting SARS-CoV-like coronaviruses. According to multiple sequence alignment, they are Y442, L472, N479, D480, T487 and Y4911 in SARS-CoV, and L455, F486, Q493, S494, N501 and Y505 in SARS-CoV-2. 26 Therefore, SARS-CoV-2 and SARS-CoV vary with respect to five of these six residues. The SARS-CoV strain genome sequences derived from humans were very close to those in bats. Even so, several differences have been identified between the gene sequences of the S gene and the ORF3 and ORF8 gene sequences that encode the attachment and fusion proteins and replication proteins, respectively. 27 Specific MERS-CoV strains derived from camels were shown to be identical to those extracted from humans, with the exception of differences between the genomic regions S, ORF4b and ORF3. 28 In addition, genome sequencing-based experiments have shown that human MERS-CoV strains are phylogenetically linked to those of bats.

However, for the S proteins, the species have a similar genome and protein structures. 29 Based on the recombination studies of orf1ab and S encoding genes, the MERS-CoV was derived from the interchange of genetic elements between coronaviruses in camels and bats. In comparison, with a 96% overall identification, the primary protease is strongly protected among SARS-CoV-2 and SARS-CoV. [29] [30] [31] The ACE2 protein is found in many mammalian body tissues, primarily in the lungs, kidneys, gastrointestinal tract, heart, liver and blood vessels. 32 ACE2 receptors are vital elements in regulating the renin-angiotensin-aldosterone system pathway. Based on structural experiments and biochemical studies, SARS-CoV-2 appears to have an RBD that strongly binds to ACE2 receptors of humans, cats, ferrets and other organisms with the homologous receptors. 33 The genome sequencing of SARS-CoV-2 in January 2020 was shown to be 96% identical to the bat coronavirus (BatCoV) RaTG13 genome and 80% identical to the SARS-CoV genome. 34 However, significant differences exist. For example, the protein 8a sequence in the SARS-CoV genome is absent in the 2019-nCoV, and the protein 8b sequence of SARS-CoV-2 is 37 amino acids longer than that in SARS-CoV. 35 Alignment sequence analysis of the CoV genome indicates nonstructural and structural proteins being 60% and 45% identical, respectively, among various types of CoVs. 36 These data show that nsps are more conservative than structural proteins. RNA viruses have a higher mutational load as a result of shorter replication times ( Figure 1 ). 36 Based on comparative genomic studies between SARS-CoV-2 and SARS-like coronaviruses, there are 380 amino acid substitutions in the nsps genes and 27 mutations in genes encoding the spike protein S of SARS-CoV-2. These variations might explain the different behavioral patterns of SARS-CoV-2 compared to SARS-CoVs. 8 For example, the primary N501 T mutation in the Spike protein of SARS-CoV-2 could have significantly increased its binding affinity to ACE2. 37 

The entry of the SARS-CoV-2 into host cells and release their genomes into target cells is dependent on a sequence of steps. The virus uses the protein spike, which is important for assessing tropism and virus transmissibility. Additionally, SARS-CoV-2 even targets human respiratory epithelial cells with ACE2 receptors, indicating a structure of RBD similar to SARS-CoV. 38 After attachment of the S1-RBD to the ACE2 receptor, host cell-surface proteases such as TMPRSS2 (transmembrane serine protease 2) act on a critical cleavage site on S2. 38 Thus, the viral RNA genome is not recognized by immune system cells. 41 The accessory proteins ORF3b and ORF6 can disrupt the IFN signaling pathway by inhibiting IRF3 and NF-KB-dependent IFNβ expression and blocking the JAK-STAT signaling pathway, respectively. Also, IFN signaling is flattened by structural proteins M and N, which result in a disturbance in TANK-binding kinase 1 (TBK1)/IKB kinase ε and TRAF3/6-TBK1-IRF3/NF-ΚB/AP1 signals. 22, 39 Because the D614 G mutation is found in the outer spike protein of the virus, this attracts a huge amount of attention from the human immune system and may therefore impair the ability of SARS-CoV-2 to avoid vaccine-induced immunity. D614 G is not in the RBD, although it is involved in the interaction between individual spike protomers that regulate their mature trimeric form on the surface of the virion by hydrogen bonding. 42 Korber et al. reported that the SARS-CoV-2 variant in the D614 G spike protein has become influential across the globe. Although clinical and in vitro evidence indicate that D614 G alters the phenotype of the virus, the effect of the mutation on replication, pathogenesis, vaccine and therapy development is relatively unknown. 43 From in vitro and clinical evidence, it is apparent that D614 G has a distinct phenotype, although it is not clear whether this is the outcome of verified adaptation to human ACE2, as well as whether it enhances transmissibility, or will have a significant impact. 43 

Early diagnosis and isolation of suspected patients play a vital role in controlling this outbreak. 44 The specificity and sensitivity of different

The typical coronavirus genome is a single-stranded, which is approximately 25-32 kb. It contains 5' caps and 3'-UTR tails. (d) Coronavirusencoding structural proteins four structural genes, including spike, envelope, membrane and nucleocapsid genes, as well as accessory proteins (3a, 3b, 6, 7a, 7b, 8b, 9b and ORFs) diagnostic techniques differs between populations and the types of equipment employed. 45 Several proceedures have been recommended for the diagnosis of COVID-19:

A. Clinical presentation COVID-19 symptoms are observed approximately 5 days after incubation. 46 The median time of symptom onset from COVID-19 incubation is 5.1 days, and those infected display symptoms for 11.5 days. 47 This duration was shown to have a close link with the patient's immune system and age. Gastrointestinal symptoms include diarrhea, vomiting and anorexia, recorded in almost 40% of patients. 48, 49 Up to 10% of patients with gastrointestinal symptoms show no signs of fever or respiratory tract infections. 50 has also been linked to hypercoagulable disease, elevating the risk of venous thrombosis. 51 There are also records of neurological symptoms (such as fatigue, dizziness and disturbed awareness), ischemic and hemorrhagic strokes, and muscle damage. 52 Many extrapulmonary symptoms comprise skin and eye manifestations.

Italian researchers have identified skin manifestations in 20% of patients. 53 The clinical outlook for children can progressively worsen as a result of respiratory failure, which could not be corrected within 1-3 days by traditional oxygen (i.e. nasal catheter 54 ) in severe cases; the hallmarks are septic shock, sepsis, extreme and continuum bleeding as a result of coagulation abnormalities, and metabolic acidosis. 55 Septic shock could cause severe damage and impair several organs, in addition to a severe pulmonary infection. When extrapulmonary system dysfunction occurs, including the circulatory and the digestive systems, septic shock is probable, and the mortality rate increases substantially. 55 Premature delivery and intrauterine hypoxia occur when the prenate is deprived of an adequate environment of oxygen. Insidious symptoms require specific care in some newborn and preterm infants. Reports have indicated a good prognosis for children within 1 or 2 weeks. 55 Children are prone to a hyperinflammatory response to COVID-19 similar to Kawasaki disease, which responds well to management, for which a new term is being coined. 56 Also, considerable research has revealed the age distribution of adolescent patients between the ages of 25 to 89 years. Many elderly patients were between 35 and 55 years, and fewer cases among newborns and infants were found. An analysis of the initial transmission dynamics of the virus showed that the median age of patients was 59 years, varying from 15 to 89 years; most (59%) were male. 48 B. Nonspecific screening tests for COVID-19 in exposed patients

The findings of most blood tests are usually nonspecific but could help determine the causes of the disease. A complete blood count typically shows a normal or low count of white blood cells and lymphopenia. C-reactive protein (CRP) and erythrocyte sedimentation rate were generally increased, which would optimally be rechecked on days 3, 5 and 7 after admission. 1 The cardinal hallmark of COVID-19 was multiple, bilateral, posterior and peripheral ground-glass opacities with or without pulmonary consolidation and, in severe cases, infiltrating shadows. 68 Autopsy analysis of a COVID-19 patient displayed fluid accumulation and hyaline membrane formation in alveolar walls, which may be the primary pathological driver of the ground-glass opacity. 69 However, further studies indicated that small patchy shadows, pleural changes, a subpleural curvilinear line and reversed halo signs are generally observed in COVID-19 patients. 70, 71 The intralobular lines and thickened interlobular septa were shown in a crazy-paving pattern on the ground-glass opacity background. 67 Also, several lobar lesions can be found in the respiratory system in children with a severe infection. Evidence showed that chest CT manifestations (pulmonary edema) reported for COVID-19 are generally close to SARS and MERS. 69 Evidence has indicated that an initial chest CT has a higher detec- consuming and cumbersome nucleic acid detection process. 66, 68 To improve the molecular diagnostic techniques for COVID-19, isothermal amplification-based methods are currently in development.

The loop-mediated isothermal amplification (LAMP) utilizes the DNA polymerase and 4 to 6 different primers binding to the distinct sequences on the target genome. 78 In the LAMP reactions, the amplified DNA is indicated by turbidity arising from a by-product of the reaction, a detectable color generated by a pH-sensitive dye, or fluorescence produced by a fluorescent dye. 79 The approach occurs at a single temperature, in less than 1 hour, and with minimal background signals. The LAMP diagnostic testing for COVID-19 is more specific and sensitive compared to the conventional RT-PCR assays and does not dependent on specialized laboratory equipment such as a thermocycler. However, as a result of the multiplicity of primers used in this method, optimizing the reaction conditions presents a major challenge. 80,81

Microarray is a rapid and high-throughput method for the COVID-19

assay. 82 As a brief summary of the protocol, the coronavirus RNA will first produce cDNA labeled with specific probes via reverse transcrip- Figure 2 ). 94, 95 Serological tests could be specific to one type of immunoglobulin, they can concurrently measure IgM and IgG antibodies, or they may be absolute antibody examinations, which often measure IgA antibodies. 96 Based on the specific procedure and device, these experiments will usually be carried out within 1-2 hours after a sample arrives in the laboratory and is loaded onto the appropriate platform. 97 Guo et al. 98 indicated that IgA and IgM antibodies have positive rates of 93.0% and 85.5% after 3-6 days, respectively. Also, 78.0% of positive IgG antibodies were detected during 10-18 days. The efficiency of detection by an IgM enzyme-linked immunposorbent assay (ELISA)

is higher than that of qPCR after 5.5 days of symptom onset. After 5 days, IgM ELISA detection is more efficient than a qPCR.

Moreover, the combination of PCR and IgM ELISA increased the detection rate by 98.5%. 98 Xiang et al. 99 RT-qPCR test. 105 Broughton et al. 106 

The authors declare that they have no conflicts of interest.

MM and HC drafted the article. MM and HC provided critical revision of the article. SB carried out native editing. NP and AE developed the theory to investigate a specific aspect and supervised the findings of the work, as well as conceived the presented idea. MM, HC, AS, SB, NP and AE discussed the results and contributed to the final manuscript submitted for publication.

Data sharing is not applicable to this review because no datasets were generated or analyzed during the present study.

https://orcid.org/0000-0001-6255-5376

Negin Parsamanesh https://orcid.org/0000-0002-1925-9165

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Going global-travel and the 2019 novel coronavirus

A novel coronavirus associated with severe acute respiratory syndrome

Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

A novel coronavirus from patients with pneumonia in China

The novel insight of SARS-CoV-2 molecular biology and pathogenesis and therapeutic options

COVID-19, SARS and MERS: are they closely related?

Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?

The outlook for diagnostic purposes of the 2019-novel coronavirus disease

Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event

Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV

Identification and characterization of Coronaviridae genomes from Vietnamese bats and rats based on conserved protein domains

Epidemiology, genome and clinical features of the pandemic SARS-CoV-2: a recent view

Neurological manifestations of coronavirus infections: role of angiotensin-converting enzyme 2 in COVID-19

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach

Processing of the SARS-CoV pp1a/ab nsp7-10 region

Genomic characterization of a novel SARS-CoV-2

SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response

Studies on membrane topology. N-Glycosylation and Functionality of SARS-CoV Membrane

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites

An analysis based on decade-long structural studies of SARS 3, JVI accepted manuscript posted online 29

MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity

Genetic characterization of Betacoronavirus lineage C viruses in bats reveals marked sequence divergence in the spike protein of pipistrellus bat coronavirus HKU5 in Japanese pipistrelle: implications for the origin of the novel Middle East respiratory syndrome coronavirus

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding

Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options

ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

The proximal origin of SARS-CoV-2

Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein

Coronavirus disease pandemic (COVID-19): challenges and a global perspective

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Overview of the pathogenesis and treatment of SARS-CoV-2 for clinicians: a comprehensive literature review

The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19)

Cell entry mechanisms of SARS-CoV-2

SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon

Making sense of mutation: what D614 G means for the COVID-19 pandemic remains unclear

Tracking changes in SARS-CoV-2 spike: evidence that D614 G increases infectivity of the COVID-19 virus

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China

Variation of a test's sensitivity and specificity with disease prevalence

COVID-19 infection: origin, transmission, and characteristics of human coronaviruses

The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan

Cutaneous manifestations in COVID-19: a first perspective

Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients

Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus

Covid-19 and Kawasaki syndrome: should we really be surprised? Cardiol Young

Presumed asymptomatic carrier transmission of COVID-19

Serum interleukin-6 and C reactive protein responses in patients after laparoscopic or conventional cholecystectomy. The European journal of surgery=

COVID-19 and the liver: little cause for concern

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics, laboratory findings, radiographic signs and outcomes of 52,251 patients with confirmed covid-19 infection: a systematic review and meta-analysis

The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019

MERS-CoV infection in humans is associated with a proinflammatory Th1 and Th17 cytokine profile

Novel therapeutic approaches for treatment of COVID-19

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreakhe epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Sensitivity of chest CT for COVID-19: comparison to RT-PCR

11C-hydroxy-ephedrine-PET/CT in the diagnosis of Pheochromocytoma and Paraganglioma

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

COVID-19 infection presenting with CT halo sign

Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing

Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results

A new coronavirus associated with human respiratory disease in China

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens

Multiple assays in a real-time RT-PCR SARS-CoV-2 panel can mitigate the risk of loss of sensitivity by new genomic variants during the COVID-19 outbreak

SARS-CoV-2 and the COVID-19 disease: a mini review on diagnostic methods

Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection

Diagnosing COVID-19: the disease and tools for detection

Recent advances and perspectives of nucleic acid detection for coronavirus

Rapid detection of SARS-CoV-2 using reverse transcription RT-LAMP method

Hu Y-q. comprehensive detection and identification of seven animal coronaviruses and human respiratory coronavirus 229E with a microarray hybridization assay

Design and application of 60mer oligonucleotide microarray in SARS coronavirus detection

Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk

Generic detection of coronaviruses and differentiation at the prototype strain level by reverse transcription-PCR and nonfluorescent low-density microarray

Initial performance evaluation of a spotted array Mobile analysis platform (MAP) for the detection of influenza a/B, RSV, and MERS coronavirus

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests

Updated SARS case definition using laboratory criteria

Quantitative and sensitive detection of SARS coronavirus nucleocapsid protein using quantum dots-conjugated RNA aptamer on chip

Nanocurcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients

Three emerging coronaviruses in two decades: The story of SARS, MERS, and now COVID-19

The coronavirus disease 2019 (COVID-19)

Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

The convalescent sera option for containing COVID-19

Immunobiology and immunotherapy of COVID-19: a clinically updated overview

Types of assays for SARS-CoV-2 testing: a review

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)

Evaluation of enzyme-linked immunoassay and colloidal gold-Immunochromatographic assay kit for detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia

Epigenetic mechanisms regulating COVID-19 infection

Nucleic acid detection with CRISPR-Cas13a/C2c2

Biology and applications of CRISPR systems: harnessing nature's toolbox for genome engineering

Ultra-sensitive and high-throughput CRISPR-powered COVID-19 diagnosis

CRISPR-Cas12-based detection of SARS-CoV-2

Loop-mediated isothermal amplification of DNA

Use of loop-mediated isothermal amplification of the IS900 sequence for rapid detection of cultured Mycobacterium avium subsp. paratuberculosis

Rapid detection of the severe acute respiratory syndrome (SARS) coronavirus by a loop-mediated isothermal amplification assay

Development of loop-mediated isothermal amplification assay for detection of human coronavirus-NL63

Detection of Middle East respiratory syndrome coronavirus using reverse transcription loopmediated isothermal amplification (RT-LAMP)

Development of fluorescent reverse transcription loop-mediated isothermal amplification (RT-LAMP) using quenching probes for the detection of the Middle East respiratory syndrome coronavirus

A rapid and specific assay for the detection of MERS-CoV

Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP

Loop mediated isothermal amplification (LAMP) assays as a rapid diagnostic for COVID-19

Two-stage isothermal enzymatic amplification for concurrent multiplex molecular detection

A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system

Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: their dynamic decay and correlations with immunological parameters and virological success

Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients

RNA virus population diversity: implications for inter-species transmission

Complete genome sequence of arracacha mottle virus

Hybrid capture-based next generation sequencing and its application to human infectious diseases

Identification and survey of a novel avian coronavirus in ducks

Complete genome sequence of a hemagglutination-negative avian paramyxovirus type 4 isolated from China

biology and novel laboratory diagnosis